Inozyme Pharma, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Inozyme Pharma, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2020 to Q3 2024.
  • Inozyme Pharma, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $710K, a 43.5% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $710K -$546K -43.5% Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $853K -$528K -38.2% Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $992K -$511K -34% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $1.13M -$494K -30.5% Dec 31, 2023 10-Q 2024-11-05
Q3 2023 $1.26M -$478K -27.6% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $1.38M -$463K -25.1% Jun 30, 2023 10-Q 2023-08-08
Q1 2023 $1.5M -$447K -22.9% Mar 31, 2023 10-Q 2023-05-09
Q4 2022 $1.62M -$433K -21.1% Dec 31, 2022 10-K 2024-03-12
Q3 2022 $1.73M -$418K -19.4% Sep 30, 2022 10-Q 2022-11-10
Q2 2022 $1.84M -$404K -18% Jun 30, 2022 10-Q 2022-08-15
Q1 2022 $1.95M -$391K -16.7% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $2.05M +$2.05M Dec 31, 2021 10-K 2023-03-22
Q3 2021 $2.15M Sep 30, 2021 10-Q 2021-11-09
Q2 2021 $2.25M Jun 30, 2021 10-Q 2021-08-11
Q1 2021 $2.34M Mar 31, 2021 10-Q 2021-05-12
Q4 2020 $0 Dec 31, 2020 10-K 2022-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.